BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//TB Alliance | Putting science to work for better, faster TB cures. - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TB Alliance | Putting science to work for better, faster TB cures.
X-ORIGINAL-URL:https://www.tballiance.org
X-WR-CALDESC:Events for TB Alliance | Putting science to work for better, faster TB cures.
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20270314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20271107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260304T080000
DTEND;TZID=America/New_York:20260304T100000
DTSTAMP:20260430T082829
CREATED:20260311T172833Z
LAST-MODIFIED:20260317T172716Z
UID:6957-1772611200-1772618400@www.tballiance.org
SUMMARY:Global TB Stakeholders 2026 Virtual Meeting
DESCRIPTION:Global TB Stakeholders Meeting Charts Faster Route to Shorter TB Cures\n\n\n\nTB Alliance’s 2026 Global TB Stakeholders Meeting brought together partners\, advocates\, and global health leaders with a focus on the promise of and significant progress in establishing a pathway to TB Alliance’s 1×1 vision for the future of TB treatment – one-month treatment for active TB and one-day treatment for latent TB infection. The event reinforced that achieving this vision depends on connecting progress across every stage of product development and introduction\, together with countries and the broader TB stakeholder community. \n\n\n\nThe meeting opened with Mitchell Warren\, the outgoing President of the Global TB Stakeholders and Executive Director of AVAC\, reflecting on a global health environment marked by uncertainty and strain\, but also by a renewed sense of possibility of aligning on what works and moving faster together. He then formally passed the leadership role to Dr. Doris Macharia\, introducing her as the incoming President of the Global TB Stakeholders. Dr. Macharia is President of the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF).  \n\n\n\nIn her acceptance\, Dr. Macharia emphasized the need to convert momentum in scientific progress into sustained collaboration—especially across high-burden settings—so that innovation does not remain confined to the pipeline\, but reaches people quickly and equitably. \n\n\n\n\n\n\n  \n  \n    \n      \n        \n        \n          \n                                \n                      \n                          \n                      \n                  \n              \n                                \n                      \n                          Open and Download PDF                      \n                  \n                        \n        \n\n      \n    \n  \n  \n\n\n\n\n\n\n\n\n\nThe scientific arc of the meeting followed the same logic: shorten\, simplify\, and strengthen treatment while ensuring the resulting advances are deliverable at scale. Dr. Mel Spigelman\, President and CEO at TB Alliance reinforced both urgency and optimism in his opening remarks\, noting that while pressures on global health are significant\, the TB field is entering a period where the “future has never looked brighter” if progress continues across the development-and-delivery continuum. Dr. Spigelman concluded by tracing a strategic and scientific pathway to achieving TB Alliance’s 1×1 vision\, which would be articulated in greater detail by subsequent speakers and rely on successes in drug development\, introduction of innovative technologies\, and a robust and responsive access program. \n\n\n\n\n\n\n  \n  \n    \n      \n        \n        \n          \n                                \n                      \n                          \n                      \n                  \n              \n                                \n                      \n                          Open and Download PDF                      \n                  \n                        \n        \n\n      \n    \n  \n  \n\n\n\n\n\n\n\n\n\nDr. Eugene Sun\, Senior Vice President of Research and Development at TB Alliance\, then began to chart out the development path of TB Alliance’s late-stage drug candidate sorfequiline and the “SPaL” regimen. Dr. Sun recounted the path to global approval and endorsement of pretomanid as both a reminder of the task at hand and a source of learnings that are being applied to the development of sorfequiline. \n\n\n\nPrimarily by presenting results from the NC-009 clinical trial\, a Phase 2 study of sorfequiline and the SPaL regimen\, Dr. Sun highlighted sorfequiline’simproved potency and potential to reduce certain safety concerns relative to bedaquiline—one of the backbones of modern DR-TB treatment—thus positioning it as a key to future treatment shortening and simplification. \n\n\n\nDr. Sun reviewed plans for a Phase 3 study to compare a four-month SPaL/M regimen against six months of BPaL/M in a drug-resistant TB population\, reflecting the program’s goal to pair scientific advancement with pragmatic learning that supports real-world adoption – including understanding performance in the context of resistance patterns. \n\n\n\n\n\n\n  \n  \n    \n      \n        \n        \n          \n                                \n                      \n                          \n                      \n                  \n              \n                                \n                      \n                          Open and Download PDF                      \n                  \n                        \n        \n\n      \n    \n  \n  \n\n\n\n\n\n\n\n\n\nAchieving 1×1 will ultimately require translating new\, safer\, and more potent TB drugs into long-acting injectable (LAI) formulations to enable dramatic leaps in treatment shortening. Dr. Raj Taneja\, Vice President of Pharmaceutical Product Development at TB Alliance\, made clear the transformative potential of LAIs and described an approach where latent TB could be diagnosed and treated on the same day with a single injection\, and where active TB could combine an oral lead-in with long-acting formulations to simplify and shorten the burden of care. Importantly\, the discussion emphasized that LAI development choices are being guided by what will be scalable and usable in high-burden settings – prioritizing affordability and adoptability\, with an eye to manufacturing and regulatory pathways that can support wide access. \n\n\n\n\n\n\n  \n  \n    \n      \n        \n        \n          \n                                \n                      \n                          \n                      \n                  \n              \n                                \n                      \n                          Open and Download PDF                      \n                  \n                        \n        \n\n      \n    \n  \n  \n\n\n\n\n\n\n\n\n\nAs the meeting agenda moved beyond near-term regimen gains\, Dr. Nader Fotouhi\, Senior Vice President and Chief Scientific Officer at TB Alliance\, highlighted why a durable discovery engine remains essential\, emphasizing that achieving ultra short treatments will require new mechanisms\, smarter design\, and—in some cases—finding alternatives to drugs whose toxicity or tolerability can constrain scale. He further highlighted the potential of host-directed therapies to enable significant treatment shortening and TB Alliance’s early-stage work to develop and apply these technologies. Dr. Fotouhi also reinforced TB Alliance’s intent and growing efforts to leverage emerging tools\, including AI-enabled approaches\, to accelerate identification and prioritization of targets and compounds in ways that can compress development timelines. \n\n\n\n\n\n\n  \n  \n    \n      \n        \n        \n          \n                                \n                      \n                          \n                      \n                  \n              \n                                \n                      \n                          Open and Download PDF                      \n                  \n                        \n        \n\n      \n    \n  \n  \n\n\n\n\n\n\n\n\n\nThe meeting then pivoted from developing a new generation of TB treatments to ensuring that they reach all around the world who need them. \n\n\n\nSandeep Juneja\, Senior Vice President of Market Access at TB Alliance\, noted that by the end of 2025\, pretomanid procurement volumes aligned with roughly 80% of the global demand for DR-TB therapy\, while still challenging the community to compress timelines further – aiming for a future in which regulatory and policy milestones translate into near-immediate availability worldwide. \n\n\n\nMr. Juneja then described how TB Alliance is applying lessons through the rollout of pretomanid to guide the development and access approach to sorfequiline\, including integrating affordability\, acceptability\, and cost-effectiveness planning earlier—during late-stage development rather than after approval—so countries are better positioned to adopt innovations without avoidable delay. He also underscored the benefits of closer collaboration with high TB burden countries across the product development pathway. \n\n\n\nMaria Diachenko\, Director of Market Access at TB Alliance\, joined Mr. Juneja to highlight several key access initiatives developed through the introduction of pretomanid that can play catalytic roles in accelerating access to next-generation treatments. Presenters pointed to Fast Track the Cure’s role in advocacy and shared learning\, PeerLINC’s peer-to-peer technical assistance model\, and digital tools such as Upskill TB\, reflecting an approach that treats community engagement and health-system readiness as core enabling conditions for impact – not add-ons. \n\n\n\n\n\n\n  \n  \n    \n      \n        \n        \n          \n                                \n                      \n                          \n                      \n                  \n              \n                                \n                      \n                          Open and Download PDF                      \n                  \n                        \n        \n\n      \n    \n  \n  \n\n\n\n\n\n\n\n\n\nMr. Juneja concluded his presentation by sharing figures representing the impact of the BPaL/M regimens to date and projected over the next decade. The data\, derived from a model developed by Johns Hopkins University\, draws from real-world data as well as future projections\, comparing a treatment environment with BPaL/M to a theoretical one that continues to use older therapies. Topline findings from the model include that the BPaL/M regimens have saved 11\,000 additional lives and approximately $100M to date\, and is projected to save nearly 200\,000 lives and more than $1 billion over the next decade. \n\n\n\nBefore moving to a question and answer session\, Dr. Spigelman concluded by emphasizing that progress in TB therapies\, combined with advances in diagnostics and vaccines\, makes a TB elimination agenda increasingly credible – provided the global community sustains partnerships and aligns around the full pathway from innovation to delivery. Dr. Spigelman argued that “now is the time” to chart a roadmap for TB elimination and even eradication as a real objective rather than a distant aspiration. \n\n\n\n\n\n\nAfter the Q&A\, Dr. Macharia closed the meeting. She noted that the Global TB Stakeholders group will offer additional deep dive webinars throughout the year and provided attendees an opportunity to weigh in on the topics they’d be most interested to learn more about. \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nThanks to everyone who joined the virtual meeting and shared thoughtful questions in the Q&A. While we couldn’t address them all live\, we’ve compiled a full Q&A with answers from our speakers – click the link below to explore the responses.\n\n\n\n\n\n\n\n\nRead the Q&A here\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nWatch the full recording of the meeting here
URL:https://www.tballiance.org/event/global-tb-stakeholders-2026-virtual-meeting/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20250220T083000
DTEND;TZID=America/New_York:20250220T100000
DTSTAMP:20260430T082829
CREATED:20250129T201254Z
LAST-MODIFIED:20260305T235358Z
UID:5714-1740040200-1740045600@www.tballiance.org
SUMMARY:Stakeholders Association 2025 Virtual Meeting
DESCRIPTION:TB Alliance at 25: Celebrating Progress\, Driving Innovation\, and Accelerating TB Eradication \n\n\n\nOn February 20\, 2025\, TB Alliance held a virtual meeting of the Stakeholders Association (SHA). The event\, “Innovate to Eradicate: The Building Blocks to End TB\,” recognized TB Alliance’s 25th anniversary and past contributions to advancing TB research and access\, while also setting forth a vision for a new era in TB treatment innovation that could allow the world to think beyond controlling TB and realistically ending TB. The meeting emphasized that achieving this vision requires strong global collaboration\, political will\, and resources. The speakers highlighted that ultra-short\, effective therapies for both active and latent TB are essential pieces in the fight toward eradication and outlined a path toward one-day treatment for latent TB and one-month treatment for active TB\, while also accelerating the availability of new TB treatments worldwide.  \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nMitchell Warren\, president of the SHA\, opened the meeting by highlighting the SHA’s historic and ongoing role in supporting TB Alliance’s pursuit of its mission—from being a part of TB Alliance’s founding to its impact today. Mr. Warren noted that developments around funding in the TB space and beyond are apt to create additional challenges but stressed the importance of continuing to advance TB innovation and the value of collaboration in doing so.  \n\n\n\nDownload Mitchell’s presentation here \n\n\n\n\n\n\n\n\n\n\n\n\nDr. Mel Spigelman\, president and CEO of TB Alliance\, echoed Warren in acknowledging the importance of the SHA and the need for adequate political will and resources to drive the pace of progress in TB and enable those around the world in need of new technologies to rapidly and sustainably access them. Dr. Spigelman recounted TB Alliance’s distinguished record in innovating the TB drug development process\, introducing improved therapies for treating pediatric TB and drug-resistant TB\, and more recently in leading the fastest and widest roll out a new TB treatment in the modern era. \n\n\n\n\n\n\n\n\n\n\n\n\n\nDr. Spigelman noted that the previous two and a half decades of leading the global TB drug development space has led to new promise and that with programs currently in development\, TB Alliance could soon realize one-month treatment regimens for all active TB (both drug-sensitive and drug-resistant)\, as well as one-day treatment for latent TB. These technologies\, which Dr. Spigelman referred to as the “1 by 1” strategy\, are the potential backbone of a toolbox of TB treatments capable of ending TB globally. \n\n\n\nDownload Mel’s presentation here \n\n\n\n\n\n\n\n\n\n\n\nWith the broader vision established\, Dr. Eugene Sun\, senior vice president of Research and Development\, outlined ongoing research programs and strategies within TB Alliance’s pipeline\, and how the organization can deliver the tools of a 1×1 approach. He focused on three key areas: developing a universal regimen\, creating a short treatment for latent TB\, and exploring delivery methods beyond small molecule therapies—such as long-acting injectables—to dramatically shorten treatment duration.  \n\n\n\nA universal regimen—a single\, novel treatment regimen capable of treating virtually all forms of active TB—is required to simplify TB treatment. Dr. Sun offered an update on the NC-009 trial\, which is testing the TBAJ876 + pretomanid + linezolid regimen\, noting that enrollment was completed ahead of schedule. While this regimen\, as administered in this trial\, does not project to be one-month in duration\, it does offer the potential to be the first universal regimen. If results from the NC-009 trial are positive\, the regimen will continue to the next stage of development.   \n\n\n\n\n\n\n\n\n\n\n\n\n\nDr. Sun discussed TB Alliance’s efforts to develop compounds for treating latent TB\, a relatively new focus for the organization. The potency of newer drug candidates raises the possibility of a single-day treatment for latent TB. Advancing a new generation of short\, simple\, and highly effective cures for both latent and active TB is key to tackling the global TB burden from both ends.  \n\n\n\n\n\n\n\nAchieving treatment durations as short as one month for active TB and one day for latent TB will likely require formulations beyond traditional pills. One promising innovation is long-acting injectables. Dr. Sun spoke on TB Alliance’s strategies to explore alternative formulations and treatment approaches\, highlighting the potential of compounds in its portfolio to support these advancements.   \n\n\n\nDownload Eugene’s presentation \n\n\n\n\n\n\n\n\n\n\n\nThe ultimate goal of any new medical technology is to reach those in need\, saving lives and maximizing impact. Sandeep Juneja\, senior vice president of Market Access\, highlighted TB Alliance’s recent successes in expanding global access to TB treatments and shared key lessons to accelerate future rollouts.  \n\n\n\nHe reviewed the global rollout of pretomanid and the BPaL/M regimens\, which became the fastest and most widespread introduction of a new TB treatment in modern history—reducing a typical 7–9-year timeline to just three years. In 2024 alone\, 100\,000 courses of pretomanid were ordered worldwide.  \n\n\n\nHowever\, Mr. Juneja emphasized that access can and should be even faster. He outlined strategies to further reduce delays\, including earlier engagement with countries\, streamlined policymaking\, improved procurement and regulatory processes\, and better integration of the private sector.  \n\n\n\nClosing his remarks\, Mr. Juneja challenged the community to envision a future where global access to groundbreaking TB treatments—like those in the pipeline—is achieved in just one year\, one month\, or even one day.  \n\n\n\nDownload Sandeep’s presentation \n\n\n\n\n\n\n\n\n\n\nThe event concluded with a question-and-answer session covering various topics\, including the practical challenges of administering long-acting injectable treatments in low-resource settings\, opportunities to align TB Alliance’s vision with the goals of the broader TB research community\, as well as the ongoing effects of funding disruptions on both TB research and service delivery. 
URL:https://www.tballiance.org/event/stakeholders-association-2025-virtual-meeting/
ATTACH;FMTTYPE=image/png:https://www.tballiance.org/wp-content/uploads/2025/01/SHA-2025_SaveTheDate.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231114T000000
DTEND;TZID=America/New_York:20231114T235959
DTSTAMP:20260430T082829
CREATED:20231106T011130Z
LAST-MODIFIED:20250129T200548Z
UID:3346-1699920000-1700006399@www.tballiance.org
SUMMARY:Stakeholders Association 2023 Annual Meeting
DESCRIPTION:TB Alliance Stakeholders Share Progress and Real-World Experiences in Ensuring Access to New Therapies\n\n\n\nOn November 14th\, 2023 TB Alliance held its annual meeting of its Stakeholders Association (SHA) and other tuberculosis (TB) and global health stakeholders to highlight recent advances in its drug development and delivery efforts. Key topics of the event included the announcement of a newly launched Pan-Phase 2 clinical trial testing the first potentially “universal TB regimen\,” an update on the global rollout and uptake of pretomanid and BPaL regimen\, and a panel discussion featuring health officials of TB-endemic countries relaying their experiences and insights regarding the adoption\, use\, and future plans for pretomanid and the BPaL regimen. \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nMitchell Warren\, SHA President\, began the event by emphasizing the importance of not only developing but effectively delivering new health technologies to those in need\, encapsulating this sentiment by noting\, “We spend so much time thinking about the research and development of new tools – but if we don’t deliver them\, they don’t really matter.” \n\n\n\nDr. Mel Spigelman\, TB Alliance President and CEO\, reflected on the evolving strategy of the organization over its history\, noting its progress from focusing on developing single drugs to regimens and identifying that the organization is once again at an inflection point. Driven by advances in science\, the promise of the pipeline\, and growing opportunities for partnership\, Dr. Spigelman commented\, “We can now see a path forward to potentially treating latent TB in a day – and as short a time period as one month for active TB.” Dr. Spigelman closed his remarks by stating\, with the input and support of key stakeholders\, the organization is once again poised for a strategic expansion\, remaining committed to all previous aspects of its work\, while expanding its focus into latent TB\, embracing new modalities of therapy\, and deepening its commitment to ensuring widespread access to new TB treatments. \n\n\n\n\nDr. Spigelman’s Slides are Available Here\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nDr. Eugene Sun\, TB Alliance Senior Vice President\, Research and Development\, introduced the recently launched Pan-Phase 2 NC-009 trial\, which will evaluate the safety and efficacy of a combination of a new experimental compound\, TBAJ-876\, with pretomanid and linezolid\, components of TB Alliance’s BPaL regimen. This regimen has the potential to shorten and improve treatment for both drug-sensitive and drug-resistant tuberculosis (TB). Dr. Sun contextualized this trial—and new potential regimens—by tracing the development and modifications of the BPaL regimen\, in pursuit of superior efficacy and tolerability. One of the chief potential benefits of the new regimens tested in NC-009 is their ability to further shorten therapy. Dr. Sun noted about the trial\, “We will learn about the potential for a (TBAJ-)876\, pretomanid\, linezolid regimen to be a treatment regimen shorter than four-months. \n\n\n\n\nDr. Sun’s Slides are Available Here\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nSandeep Juneja\, TB Alliance Senior Vice President\, Market Access provided an overview of progress in enabling and expanding access to pretomanid and the BPaL regimen. Mr. Juneja highlighted the speed at which TB Alliance has been able to achieve this\, crediting that to planning\, partnerships\, and coordination\, noting “We worked deliberately to ensure many access activities happened in parallel – that has allowed us to enable access to happen within three years.” Since approval\, pretomanid has been ordered by 70 countries\, in volume to treat 40\,000 people with DR-TB. Mr. Juneja contextualized this achievement by stating that access has traditionally taken as long as nine years to achieve and the reach of pretomanid has expanded significantly more quickly than past new TB therapies. Mr. Juneja reiterated TB Alliance’s deepening commitment to access work\, facilitating information and experience sharing\, and beginning work for next stage products. \n\n\n\n\nMr. Juneja’s Slides are Available Here\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nA robust panel discussion was introduced and moderated by Oxana Rucsineanu of Moldova and Priyanka Aiyer of India. In introducing the panel\, Ms. Rucsineanu recalled her experience as an MDR-TB survivor\, recounting having to take 36 months of treatment and noting that shorter and efficient therapy\, like BPaL\, is “what we fight for.” Ms. Aiyer followed by emphasizing the importance of access\, remarking that “The BPaL regimen offers an incredible chance to bring change” to past and ongoing struggles for access to key technologies and the discourse around them. Ms. Aiyer urged the community to “focus on what really matters—the wellbeing of people who are affected by TB.” \n\n\n\nThe panel discussion focused on real-world progress and challenges in adopting pretomanid-containing therapies and plans for further expanding the availability of new TB cures. Lada Bulakh\, Member of Parliament\, Committee on Epidemic Security\, HIV/AIDS\, and Socially Dangerous Diseases\, Ukraine discussed the process of translating the evidence supporting the adoption of pretomanid and BPaL for treating drug-resistant TB into legislation and policy amid violence in the Ukraine. Ms. Bulakh is proud of Ukraine’s swift progress on this front (Ukraine was the first country to adopt BPaL)\, declaring\, “Ukraine is one of the leaders in implementing—with support of WHO—innovative\, shortened treatments and new drugs\, such as pretomanid.” \n\n\n\n\n\n\n\n\n\nAddul Ghafoor\, MDR-TB Advisor to National TB Program\, Ministry of Health\, Pakistan focused on the importance of coordination and planning to quickly facilitate access. Mr. Ghafoor stated that Pakistan\, which has recently updated its national TB treatment guidelines to include BPaL\, intends to treat 85% of MDR-TB patients on BPaL beginning in 2024. Mr. Ghafoor remarked that to achieve this\, “What we need to do is multipronged\, simultaneous\, and fast.” \n\n\n\nSiti Nadia Tarmizi\, Director of Communications Bureau\, Ministry of Health Indonesia noted that in addition to operational challenges\, trainings\, and formal process of transitioning from operational research to programmatic scale-up of BPaL\, addressing perception from TB affected communities and soliciting input from physicians was critical to the country’s process in rolling out pretomanid-containing regimens. In considering what it takes to achieve this transition\, Ms. Tarmizi noted\, it “reflects a comprehensive infrastructure to support implementation.” \n\n\n\nFernanda Dockhorn\, National TB Program\, Ministry of Health\, Brazil stated that a significant source of challenges in accelerating access to pretomanid and BPaL is the process of integrating new health technologies into the national public health system. Ms. Dockhorn went on to report that\, “The process is ongoing; we are planning to [to have] the medicine in the beginning of next year (2024).” A series of training programs will follow. Ms. Dockhorn praised the value of engaging civil society in this effort. \n\n\n\nNorbert Ndjeka\, Chief Director\, TB Control and Management\, National Department of Health\, South Africa provided an update on South Africa’s progress in rolling out pretomanid-containing therapies\, citing that seven of nine provinces are currently treating those with DR-TB with pretomanid. Mr. Ndjeka stated\, “By the end of December (2023)\, all eligible people will be [treated with pretomanid]\, so we’ve developed a dashboard and we send the results to each province each week.” \n\n\n\nThe meeting concluded with a question-and-answer session featuring all panelists and speakers throughout the event\, which was moderated by Mitchell Warren.
URL:https://www.tballiance.org/event/stakeholders-association-2023-annual-meeting/
LOCATION:Paris Marriott Champs Elysees Hotel\, 70 Av. des Champs-Élysées\, Paris\, 75008\, France
END:VEVENT
END:VCALENDAR